^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IOV-4001

    i
    Associations
    News

    Trials

    Company:
    Iovance Biotherap
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer (IOV-GM1-201) (NCT05361174)
    Phase 1/2
    Iovance Biotherapeutics, Inc.
    Recruiting
    Last update posted :
    08/22/2023
    Initiation :
    07/20/2022
    Primary completion :
    06/01/2025
    Completion :
    06/01/2027
    BRAF
    |
    BRAF mutation
    |
    cyclophosphamide • IOV-4001